摘要
目的 :探讨罗格列酮联合二甲双胍治疗多囊卵巢综合征 (PCOS)的临床疗效。方法 :10 0例临床上有PCOS表现的肥胖不育患者通过口服葡萄糖耐量试验 (OGTT)、胰岛素及C肽释放试验 ,检出胰岛素抵抗 (IR)患者 80例 ,随机分为A、B、C 3组 ,分别给予促排卵药 ,促排卵药加二甲双胍 ,促排卵药加二甲双胍加罗格列酮 ,共治疗 2个月经周期 ,比较 3组用药前后及 3组间体重指数 (BMI)、胰岛素抵抗指数 (HomaIR)、游离脂肪酸(FFA)、肿瘤坏死因子α(TNFα)、纤溶酶原激活抑制物 1(PAI 1)和排卵率的变化。结果 :C组患者治疗后的BMI、HomaIR、FFA、TNFα、PAI 1较治疗前明显下降 (P <0 .0 5 )。C组的排卵率明显优于A组 (P <0 .0 1)和B组 (P <0 .0 5 )。结论 :罗格列酮联合二甲双胍治疗PCOS效果显著。
Objective:To evaluate the efficacy of rosiglitazone therapy combined with metformin in patients with polycystic ovary syndrome(PCOS).Methods:80 cases of insulin-resistance(IR) were selected by oral glucose tolerance test(OGTT) from 100 cases of the fat and infertility with PCOS,serum insulin was determined.The 80 cases were divided randomly into three groups:group A received ovulation-stimulating drug only,group B received ovulation-stimulating drug and metformin,group C received ovulation-stimulating drug and rosiglitazone and metformin,and all patients were treated for two menstrual cycles.The body mass index(BMI),insulin resistance homa model(HomaIR),free fatty acids(FFA),tumor necrosis factor α(TNFα),plasminogen activator inhibitor-1(PAI-1) and the ovulation rate were compared before and after the treatment,and compared them each others after the treatment simultaneously.Results:In the patients who received rosiglitazone and metformin treatment,BMI,HomaIR,serum levels of FFA and TNFα and plasma level of PAI-1 were decreased significantly after treatment(P<0.05).The ovulation rate of group C were remarkably higher than those in the group A and group B respectively(P<0.01 and P<0.05).Conclusion:Rosiglitazone and metformin can be effectivelyused to treat PCOS.
出处
《现代妇产科进展》
CSCD
2004年第3期197-199,共3页
Progress in Obstetrics and Gynecology
